Biologica Raises $7 Million Seed Funding to Expand Stage‑Specific Women’s Health Supplements
Biologica, a San Francisco–based women’s health and wellness startup developing stage‑specific daily supplements tailored to different phases of hormonal life — from reproductive years through perimenopause and postmenopause — has raised $7 million in a seed funding round to scale its operations, broaden its product offerings, and deepen its scientific and market reach. The fundraising marks an important financial milestone as the company moves to solidify its position in the rapidly growing femtech and nutraceutical sectors.
The seed round was led by Addition, a venture capital firm known for backing startups with long-term growth potential across consumer, enterprise, and technology sectors. Participation in the round came from a diverse group of investors with expertise in consumer health, venture capital, and brand-driven businesses, reflecting strong confidence in Biologica’s vision and execution. Contributing investors included Hawktail, Greycroft, True Beauty Ventures, Good Friends Venture Capital, as well as prominent individual backers such as Gabrielle Bernstein and Katherine Schwarzenegger Pratt.
Biologica was co‑founded by Elizabeth “Liz” Zwillinger and Joseph “Joey” Zwillinger. Joey Zwillinger is also known as co‑founder of the sustainable footwear brand Allbirds, bringing seasoned consumer brand experience to the startup. The company’s product line is centered around effervescent daily supplements — formulated for specific hormonal phases — that combine clinically studied ingredients in research-backed dosages. These products are designed to address common symptoms women experience at different life stages, such as mood swings, sleep disruptions, digestive issues, cognitive concerns, and metabolic changes.
The initial set of offerings includes Primary Essentials, formulated for the reproductive years to support mood, skin health, and premenstrual symptoms; Midlife Essentials for perimenopause challenges such as irritability and brain fog; and Postmenopause Essentials, which focuses on cognition, bone strength, heart health, and cellular function. Each formula incorporates targeted probiotic strains, vitamin complexes, electrolytes, and botanicals at clinically relevant doses intended to support women through life’s hormonal transitions.
In announcing the funding, Biologica’s founders emphasized that the company was built out of a real-world need for health solutions that meet women where they are in their hormonal journeys. The motivation behind Biologica’s product design stems from personal experience and broader discussions with other women navigating hormonal shifts without clear, dependable guidance — a gap the company aims to fill through science-backed formulations and accessible delivery formats.
The newly secured capital will be used to scale Biologica’s manufacturing and distribution capabilities, enhancing research and development efforts for future products and expanding its market presence. The funding round also supports investments in scientific validation and clinical insight, helping the company build further credibility in an emerging wellness category that integrates nutritional science with women’s health.
Biologica’s supplements are currently sold through its direct-to-consumer channels, where subscription offerings have been designed to encourage ongoing use and support. The infusion of seed capital places the company in a strong strategic position to deepen engagement with customers and scale its operations both domestically and internationally.
Investor interest in Biologica reflects broader industry momentum toward personalized wellness and femtech innovation, where tailored health solutions for women’s unique physiological needs are increasingly valued by consumers and investors alike. By combining targeted formulations with clinically supported ingredients and a strong brand narrative, Biologica seeks to differentiate itself in a crowded supplement market and build long-term resonance with women looking for solutions grounded in both science and lived experience.
As the company scales with its $7 million seed raise, Biologica is poised to expand its product roadmap, further integrate medical expertise into product development, and continue advocating for nuanced approaches to women’s health that acknowledge hormonal diversity across life stages. The startup’s early success underscores the growing demand for personalized, stage-specific nutritional support and positions Biologica as a notable player in the evolving landscape of consumer health innovation.
